AlphAIalphai — Financial news for AI agents
fool.comSEP 13 min read$MRNA

Moderna Stock More Than Doubled in August. Is the Stock a Buy, a Hold, or a Sell?

Moderna's stock surged 150% in August after positive trial results for its personalized mRNA cancer vaccine with Merck's Keytruda. The company's revenue peaked at $18B with its COVID-19 vaccine but faced declines due to reduced demand. Moderna has since expanded its pipeline, including approvals for updated COVID-19, RSV, and flu vaccines. The stock's recent gains may be priced in, and investors should consider waiting for a potential pullback.

Original reporting
fool.com
Published Sep 1, 2026, 10:15 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 1, 2026, 10:29 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Moderna Stock More Than Doubled in August. Is the Stock a Buy, a Hold, or a Sell? — source image
Source · fool.com
Decision brief

The 30-second read

$MRNABullishMed
01

Why it matters

The new trial data is a primary disclosure that could materially affect valuation and investor sentiment.

02

Market read

First report of pivotal oncology trial results, driving a massive intraday rally and prompting re‑evaluation of the stock.

03

What to watch

Potential reimbursement challenges and competition from other personalized cancer vaccine programs.

Relevance 8/10Novelty 8/10Timing: today

Background

The article reviews Moderna's historic stock surges and recent trial success, framing a buy‑hold‑sell question.

Company-level read

Ticker impact

$MRNABullishHigh confidence
Context

Moderna announced positive Phase 3 data for its personalized mRNA cancer vaccine combined with Merck's Keytruda, driving a 177% one‑day stock surge.

Expected impact

Potential continued rally if regulatory filing follows; watch for pull‑back after sharp move.

Evidence & confidence

Phase 3 results are material and rare for a biotech; market reacted strongly, indicating high relevance.

Market effects

Sector

Positive oncology data may lift other mRNA and cancer‑immunotherapy stocks.

Regional

US biotech sector could see increased investor inflows.

Global

Global interest in mRNA platforms may rise, affecting peers worldwide.

Counterpoint

What could challenge this read

The steep price run may be overbought; regulatory approval is uncertain and manufacturing costs are high.

Key entities

  • company
    Moderna

    Biotech firm developing mRNA therapeutics.

  • company
    Merck

    Partner providing Keytruda for the combination trial.

Read at source← All news

Related articles

SEP 1
$MRNAHighAI 9/10

Why is Moderna stock rallying today?

Moderna (MRNA) stock rose 4.9% to $147.17, recovering from a recent pullback, after its mRNA cancer vaccine met primary endpoints in a Phase 3 trial with Merck. Argus upgraded MRNA to Buy with a $180 target, citing its oncology pipeline and vaccine portfolio. The company will participate in upcoming investor conferences. BioNTech's recent setback may also be benefiting Moderna. The S&P 500 and Nasdaq fell 0.5% and 0.7%, respectively.

investing.com2 min
SEP 1
$MRNAHighAI 9/10

Moderna (MRNA) Soars 156% in August — Here’s What Propelled The Rally

Moderna (MRNA) shares surged 156% in August, driven by positive clinical trial results for its melanoma therapy and FDA approval for updated COVID-19 vaccines. The company's therapy, in partnership with Merck, met primary and secondary endpoints, showing improvement over Keytruda alone. Moderna also reported increased hedge fund holdings and highlighted the large market potential for its melanoma treatment.

insidermonkey.com2 min
AUG 31
$MRNAMed

MRNA Looks 476.4% Overvalued on GF Value™

Moderna Inc (MRNA) shares rose 0.71% to $138.97 on August 31, 2026, with bullish options activity. The company's P/S ratio is 24.69, above its historical median of 8.4, indicating high growth expectations. GuruFocus' GF Value™ suggests MRNA is 476.4% overvalued. Insider activity shows $47.8M in selling over 12 months, while guru holdings are mixed.

gurufocus.com3 min
AUG 31
$PFELowAI 8/10

FDA Approves New Covid Shots From Pfizer and Moderna

FDA approved updated Covid vaccines from Pfizer (Comirnaty XFG) and Moderna (Spikevax, mNEXSPIKE) targeting the XFG variant for the 2026-2027 season. Approvals were based on mouse studies and prior human data, with human trials for the new formulations not yet started. The shots are approved for specific age groups and high-risk individuals. Both companies expect rapid availability. The approvals follow substantial government contracts and include warnings for myocarditis and pericarditis.

thenewamerican.com3 min
AUG 31
$MRKMedAI 8/10

Merck and Moderna's cancer vaccine is customized for each patient

Merck & Co. and Moderna developed a personalized cancer vaccine, customized for each patient's tumor genome, to be used with Merck's Keytruda. The FDA granted Breakthrough Therapy designation in 2023. Phase 3 trials showed a 44% reduction in recurrence risk for melanoma patients. The companies are also exploring its use in lung, renal cell, and bladder cancers.

drugdiscoverytrends.com2 min
AUG 31
$MRNAMedAI 8/10

Jim Cramer Called Moderna Inc. (NASDAQ:MRNA) & Merck’s Trial Results Encouraging

Moderna (MRNA) and Merck (MRK) stocks surged after announcing positive late-stage melanoma vaccine trial results. The trial combined Moderna's mRNA technology with Merck's Keytruda drug. Analysts from Bank of America and Morgan Stanley raised price targets for Moderna, citing the vaccine's potential. Merck reported strong sales growth for Keytruda and other drugs, but posted a net loss in Q2. Hedge fund activity and short interest were noted for both companies.

insidermonkey.com2 min